AI Digest · Lawsuit says Abbott sales reps adjusted spinal stimulators without a license as shares slip
A South Carolina woman sued Abbott in federal court in Illinois. She says unlicensed Abbott sales reps told her a failed Proclaim spinal cord stimulator could be reprogrammed. Abbott stock fell 0.4% over the last day to $103.68. Most of the slide came after midday. Abbott narrowed its 2026 sales growth outlook to about 6% this week. The company is also preparing to spin off its Similac and Ensure nutrition business.
Abbott Laboratories makes medical devices, diagnostic tests, nutrition products such as Similac and Ensure, and generic medicines. Its diabetes devices, including the FreeStyle Libre glucose monitor, are among its fastest-growing products. This contract tracks the price of Abbott stock (ABT).
What to watch: Quarterly earnings, medical device sales, and product approvals.
Social